<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335030">
  <stage>Registered</stage>
  <submitdate>15/01/2010</submitdate>
  <approvaldate>20/01/2010</approvaldate>
  <actrnumber>ACTRN12610000067077</actrnumber>
  <trial_identification>
    <studytitle>A novel cell therapy to treat patients with hepatitis C virus (HCV)infection.</studytitle>
    <scientifictitle>Safety and efficacy of cell immunotherapy to treat hepatitis C virus (HCV) infection</scientifictitle>
    <utrn>U1111-1113-3407</utrn>
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C virus infection</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cell immunotherapy to elicit HCV-specific immune responses in patients who have previously failed interferon-based therapy.
The dose will vary from 10,000  to 100 million HCV antigen positive cells, administered by the intradermal route. Patients will receive these cell numbers in 1, 2 or 3 doses with one week between doses.</interventions>
    <comparator>Patients will represent their own control as the viral load and immunological parameters will be studied before and after intervention.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety.
Clinical examination.
Haematology-full blood examination
Clinical chemistry-full study, including liver function tests (LFT).
HCV viral load.</outcome>
      <timepoint>Weekly during intervention and weekly for 6 weeks after intervention.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Induction of HCV-specific cell mediated immunity.
This will be assessed by Enzyme-linked immunosorbent spot (ELIspot) examination of peripheral blood mononuclear cells (PBMC) using HCV peptide pools as the stimulating antigen.
The viral load will be assessed by reverse transcriptase-polymerase chain reaction (RT-PCR).</outcome>
      <timepoint>Weekly during intervention and weekly for 6 weeks after intervention.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>HCV ribonuclei acid (RNA) positive for &gt;6 months.
Previously failed interferon-based therapy
Infected with genotype 1 virus.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Hepatitis B virus (HBV)-positive
Human immunodeficiency virus (HIV)-positive
Evidence of autoimmunity</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>The patients will be enrolled by a clinician who normally provides care. The trial will be discussed during a normal appointment in the liver clinic, the patient provided with a patient information and consent form (PICF) which he/she is encouraged to read and discuss with family/friends and/or their general practitioner. The consent form will be signed in the clinic in the presence of their liver specialist.</concealment>
    <sequence>Patients will be enrolled essentially as they appear in the clinic.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>The trial will be a dose escalation trial.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/07/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Eric J Gowans</primarysponsorname>
    <primarysponsoraddress>Burnet Institute
GPO Box 2284
Melbourne
VIC 3001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>NHMRC
GPO Box 1421
Canberra, ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Alfred Hospital</othercollaboratorname>
      <othercollaboratoraddress>Dr Stuart Roberts
Dept of Gastroenterology
Commercial Road
Melbourne
VIC 3004</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is designed to examine the hypothesis that increasing the level of specific immunity to the proteins of hepatitis C virus will result in a reduction in the viral load and/or clearance of the virus.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Medical Research and Education Precinct (AMREP).</ethicname>
      <ethicaddress>Alfred Hospital
Commercial Road
Melbourne
VIC 3004</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>18/01/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eric Gowans</name>
      <address>Burnet Institute
GPO Box 2284
Melbourne, VIC 3001</address>
      <phone>61 8 8161 8541/61 422928906</phone>
      <fax>61 8 8239 0267</fax>
      <email>eric.gowans@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bruce Loveland</name>
      <address>Burnet Institute
GPO Box 2284
Melbourne
VIC 3001</address>
      <phone>61 3 9282 2111</phone>
      <fax>61 3 9282 2100</fax>
      <email>bloveland@burnet.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Eric Gowans</name>
      <address>Burnet Institute
GPO Box 2284
Melbourne, VIC 3001</address>
      <phone>61 8 8161 8541/61 422 928 906</phone>
      <fax>61 8 9239 0267</fax>
      <email>eric.gowans@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>